Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.
Mansoor Raza MirzaGabriel LindahlSven MahnerAndrés RedondoMichel FabbroBobbie J RimelJørn HerrstedtAmit M OzaUlrich CanzlerJonathan S BerekAntonio Gonzáles MartinPhillipe FollanaRosemary LordMasoud AzodiKasey EstensonZebin WangYong LiDivya GuptaUrsula A MatulonisBin FengPublished in: Cancer research communications (2022)
HRR mutations generally benefited from second-line maintenance treatment with niraparib compared with placebo.